Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-08-11

AUTHORS

Keqian Zhang, Wenwei Wang, Ting Zhang, Lan Liang

ABSTRACT

BackgroundMultitargeted tyrosine kinase inhibitors (TKIs) are used to treat advanced non-small cell lung cancer (NSCLC). Their efficacy and safety have been studied in randomized controlled trials.AimThis meta-analysis aimed to summarize the most up-to-date evidence regarding the efficacy and adverse events of TKIs in NSCLC treatment.MethodRandomized controlled trials were searched from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. The intervention arm was the TKI-containing group, and the control arm was the TKI-free group. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival, and adverse events were extracted and synthesized. The last search was performed in April 2022. Two researchers independently screened articles, extracted data, and evaluated the quality of the included studies. The Cochrane risk-of-bias tool was used to assess the quality of each study. Random or fixed-effect models were used in statistical methods. I2 statistics were used to assess heterogeneity.ResultsThirty-one studies (12,517 patients) were included. Compared to the control group, the TKI group had significantly higher ORR (relative risk RR 1.52, 95% confidence interval, CI [1.29, 1.80], P < 0.05), DCR (RR 1.34, 95%CI [1.19, 1.51], P < 0.05), and prolonged PFS (hazard ratio HR 0.67, 95%CI [0.59, 0.77], P < 0.05). The TKI group showed a higher rate of adverse events (RR 1.70, 95%CI [1.34, 2.16], P < 0.05) and grade 3–5 adverse events (RR 1.59, 95% CI [1.35, 1.88], P < 0.05).ConclusionTKIs could increase ORR and DCR and prolong PFS for advanced NSCLC. Adverse events should be closely monitored. More... »

PAGES

1-15

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11096-022-01465-w

DOI

http://dx.doi.org/10.1007/s11096-022-01465-w

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1150157341

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35951217


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Oncology, The First Hospital Affiliated to Army Medical University, Chongqing, China", 
          "id": "http://www.grid.ac/institutes/grid.410570.7", 
          "name": [
            "Department of Oncology, The First Hospital Affiliated to Army Medical University, Chongqing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Keqian", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory, The First Hospital Affiliated to Army Medical University, Chongqing, China", 
          "id": "http://www.grid.ac/institutes/grid.410570.7", 
          "name": [
            "Department of Respiratory, The First Hospital Affiliated to Army Medical University, Chongqing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Wenwei", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China", 
          "id": "http://www.grid.ac/institutes/grid.412461.4", 
          "name": [
            "Department of Respiratory, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Ting", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory, The First Hospital Affiliated to Army Medical University, Chongqing, China", 
          "id": "http://www.grid.ac/institutes/grid.410570.7", 
          "name": [
            "Department of Respiratory, The First Hospital Affiliated to Army Medical University, Chongqing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liang", 
        "givenName": "Lan", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11864-020-0714-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1124803841", 
          "https://doi.org/10.1007/s11864-020-0714-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2017.478", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101006851", 
          "https://doi.org/10.1038/bjc.2017.478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-14-290", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044098763", 
          "https://doi.org/10.1186/1471-2407-14-290"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-08-11", 
    "datePublishedReg": "2022-08-11", 
    "description": "BackgroundMultitargeted tyrosine kinase inhibitors (TKIs) are used to treat advanced non-small cell lung cancer (NSCLC). Their efficacy and safety have been studied in randomized controlled trials.AimThis meta-analysis aimed to summarize the most up-to-date evidence regarding the efficacy and adverse events of TKIs in NSCLC treatment.MethodRandomized controlled trials were searched from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. The intervention arm was the TKI-containing group, and the control arm was the TKI-free group. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival, and adverse events were extracted and synthesized. The last search was performed in April 2022. Two researchers independently screened articles, extracted data, and evaluated the quality of the included studies.\u00a0The Cochrane risk-of-bias tool was used to assess the quality of each study. Random or fixed-effect models were used in statistical methods.\u00a0I2 statistics were used to assess heterogeneity.ResultsThirty-one studies (12,517 patients) were included. Compared to the control group, the TKI group had significantly higher ORR (relative risk RR 1.52, 95% confidence interval, CI [1.29, 1.80],\u00a0P\u2009<\u20090.05), DCR (RR 1.34, 95%CI [1.19, 1.51], P\u2009<\u20090.05), and prolonged PFS (hazard ratio HR 0.67, 95%CI [0.59, 0.77], P\u2009<\u20090.05). The TKI group showed a higher rate of adverse events (RR 1.70, 95%CI [1.34, 2.16], P\u2009<\u20090.05) and grade 3\u20135 adverse events (RR 1.59, 95% CI [1.35, 1.88], P\u2009<\u20090.05).ConclusionTKIs could increase ORR and DCR and prolong PFS for advanced NSCLC. Adverse events should be closely monitored.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11096-022-01465-w", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1044817", 
        "issn": [
          "2210-7703", 
          "2210-7711"
        ], 
        "name": "International Journal of Clinical Pharmacy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }
    ], 
    "keywords": [
      "non-small cell lung cancer", 
      "objective response rate", 
      "disease control rate", 
      "progression-free survival", 
      "tyrosine kinase inhibitors", 
      "advanced non-small cell lung cancer", 
      "adverse events", 
      "cell lung cancer", 
      "TKI group", 
      "Controlled Trials", 
      "lung cancer", 
      "multi-targeted tyrosine kinase inhibitor", 
      "treatment-related adverse events", 
      "higher objective response rate", 
      "prolong progression-free survival", 
      "kinase inhibitors", 
      "Cochrane Central Register", 
      "ResultsThirty-one studies", 
      "fixed-effects model", 
      "Central Register", 
      "overall survival", 
      "Cochrane risk", 
      "bias tool", 
      "intervention arm", 
      "NSCLC treatment", 
      "control rate", 
      "control arm", 
      "grade 3", 
      "last search", 
      "date evidence", 
      "response rate", 
      "control group", 
      "trials", 
      "efficacy", 
      "high rate", 
      "cancer", 
      "survival", 
      "group", 
      "inhibitors", 
      "EMBASE", 
      "arm", 
      "PubMed", 
      "study", 
      "events", 
      "rate", 
      "treatment", 
      "risk", 
      "Register", 
      "safety", 
      "evidence", 
      "quality", 
      "heterogeneity", 
      "search", 
      "data", 
      "statistical methods", 
      "statistics", 
      "tool", 
      "method", 
      "article", 
      "model", 
      "researchers"
    ], 
    "name": "Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials", 
    "pagination": "1-15", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1150157341"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11096-022-01465-w"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35951217"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11096-022-01465-w", 
      "https://app.dimensions.ai/details/publication/pub.1150157341"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_922.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11096-022-01465-w"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11096-022-01465-w'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11096-022-01465-w'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11096-022-01465-w'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11096-022-01465-w'


 

This table displays all metadata directly associated to this object as RDF triples.

150 TRIPLES      21 PREDICATES      86 URIs      75 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11096-022-01465-w schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Na715f503fd2641649ffcbfbff95e2154
4 schema:citation sg:pub.10.1007/s11864-020-0714-6
5 sg:pub.10.1038/bjc.2017.478
6 sg:pub.10.1186/1471-2407-14-290
7 schema:datePublished 2022-08-11
8 schema:datePublishedReg 2022-08-11
9 schema:description BackgroundMultitargeted tyrosine kinase inhibitors (TKIs) are used to treat advanced non-small cell lung cancer (NSCLC). Their efficacy and safety have been studied in randomized controlled trials.AimThis meta-analysis aimed to summarize the most up-to-date evidence regarding the efficacy and adverse events of TKIs in NSCLC treatment.MethodRandomized controlled trials were searched from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. The intervention arm was the TKI-containing group, and the control arm was the TKI-free group. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival, and adverse events were extracted and synthesized. The last search was performed in April 2022. Two researchers independently screened articles, extracted data, and evaluated the quality of the included studies. The Cochrane risk-of-bias tool was used to assess the quality of each study. Random or fixed-effect models were used in statistical methods. I2 statistics were used to assess heterogeneity.ResultsThirty-one studies (12,517 patients) were included. Compared to the control group, the TKI group had significantly higher ORR (relative risk RR 1.52, 95% confidence interval, CI [1.29, 1.80], P < 0.05), DCR (RR 1.34, 95%CI [1.19, 1.51], P < 0.05), and prolonged PFS (hazard ratio HR 0.67, 95%CI [0.59, 0.77], P < 0.05). The TKI group showed a higher rate of adverse events (RR 1.70, 95%CI [1.34, 2.16], P < 0.05) and grade 3–5 adverse events (RR 1.59, 95% CI [1.35, 1.88], P < 0.05).ConclusionTKIs could increase ORR and DCR and prolong PFS for advanced NSCLC. Adverse events should be closely monitored.
10 schema:genre article
11 schema:isAccessibleForFree false
12 schema:isPartOf sg:journal.1044817
13 schema:keywords Central Register
14 Cochrane Central Register
15 Cochrane risk
16 Controlled Trials
17 EMBASE
18 NSCLC treatment
19 PubMed
20 Register
21 ResultsThirty-one studies
22 TKI group
23 advanced non-small cell lung cancer
24 adverse events
25 arm
26 article
27 bias tool
28 cancer
29 cell lung cancer
30 control arm
31 control group
32 control rate
33 data
34 date evidence
35 disease control rate
36 efficacy
37 events
38 evidence
39 fixed-effects model
40 grade 3
41 group
42 heterogeneity
43 high rate
44 higher objective response rate
45 inhibitors
46 intervention arm
47 kinase inhibitors
48 last search
49 lung cancer
50 method
51 model
52 multi-targeted tyrosine kinase inhibitor
53 non-small cell lung cancer
54 objective response rate
55 overall survival
56 progression-free survival
57 prolong progression-free survival
58 quality
59 rate
60 researchers
61 response rate
62 risk
63 safety
64 search
65 statistical methods
66 statistics
67 study
68 survival
69 tool
70 treatment
71 treatment-related adverse events
72 trials
73 tyrosine kinase inhibitors
74 schema:name Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials
75 schema:pagination 1-15
76 schema:productId N0d915f3d18914c338019060a2f819da3
77 N5b4beb90d79d4d80a2eb69700f3d3837
78 Na6b97c61f30243da841f2124ec26ef55
79 schema:sameAs https://app.dimensions.ai/details/publication/pub.1150157341
80 https://doi.org/10.1007/s11096-022-01465-w
81 schema:sdDatePublished 2022-12-01T06:43
82 schema:sdLicense https://scigraph.springernature.com/explorer/license/
83 schema:sdPublisher Nbdc7f9dda14e46aa89f9cbc2c4467958
84 schema:url https://doi.org/10.1007/s11096-022-01465-w
85 sgo:license sg:explorer/license/
86 sgo:sdDataset articles
87 rdf:type schema:ScholarlyArticle
88 N0d915f3d18914c338019060a2f819da3 schema:name doi
89 schema:value 10.1007/s11096-022-01465-w
90 rdf:type schema:PropertyValue
91 N2f3f95e69ed74e4f9c0d6b5d48ad0f19 schema:affiliation grid-institutes:grid.410570.7
92 schema:familyName Liang
93 schema:givenName Lan
94 rdf:type schema:Person
95 N47b19b05cc5c4a718fc1580337a3b361 rdf:first N2f3f95e69ed74e4f9c0d6b5d48ad0f19
96 rdf:rest rdf:nil
97 N5b4beb90d79d4d80a2eb69700f3d3837 schema:name dimensions_id
98 schema:value pub.1150157341
99 rdf:type schema:PropertyValue
100 N600b8eaa97794dfab188c5fb5eb4d42b schema:affiliation grid-institutes:grid.410570.7
101 schema:familyName Wang
102 schema:givenName Wenwei
103 rdf:type schema:Person
104 N61b43f068c9f400e949a2791fca60cb7 rdf:first N600b8eaa97794dfab188c5fb5eb4d42b
105 rdf:rest N66b852684572488493ec608f854fe6e7
106 N66b852684572488493ec608f854fe6e7 rdf:first N9923d30a731b4bd3903463cda65c361c
107 rdf:rest N47b19b05cc5c4a718fc1580337a3b361
108 N6f280c714911462a871f75d022a04587 schema:affiliation grid-institutes:grid.410570.7
109 schema:familyName Zhang
110 schema:givenName Keqian
111 rdf:type schema:Person
112 N9923d30a731b4bd3903463cda65c361c schema:affiliation grid-institutes:grid.412461.4
113 schema:familyName Zhang
114 schema:givenName Ting
115 rdf:type schema:Person
116 Na6b97c61f30243da841f2124ec26ef55 schema:name pubmed_id
117 schema:value 35951217
118 rdf:type schema:PropertyValue
119 Na715f503fd2641649ffcbfbff95e2154 rdf:first N6f280c714911462a871f75d022a04587
120 rdf:rest N61b43f068c9f400e949a2791fca60cb7
121 Nbdc7f9dda14e46aa89f9cbc2c4467958 schema:name Springer Nature - SN SciGraph project
122 rdf:type schema:Organization
123 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
124 schema:name Medical and Health Sciences
125 rdf:type schema:DefinedTerm
126 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
127 schema:name Oncology and Carcinogenesis
128 rdf:type schema:DefinedTerm
129 sg:journal.1044817 schema:issn 2210-7703
130 2210-7711
131 schema:name International Journal of Clinical Pharmacy
132 schema:publisher Springer Nature
133 rdf:type schema:Periodical
134 sg:pub.10.1007/s11864-020-0714-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124803841
135 https://doi.org/10.1007/s11864-020-0714-6
136 rdf:type schema:CreativeWork
137 sg:pub.10.1038/bjc.2017.478 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101006851
138 https://doi.org/10.1038/bjc.2017.478
139 rdf:type schema:CreativeWork
140 sg:pub.10.1186/1471-2407-14-290 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044098763
141 https://doi.org/10.1186/1471-2407-14-290
142 rdf:type schema:CreativeWork
143 grid-institutes:grid.410570.7 schema:alternateName Department of Oncology, The First Hospital Affiliated to Army Medical University, Chongqing, China
144 Department of Respiratory, The First Hospital Affiliated to Army Medical University, Chongqing, China
145 schema:name Department of Oncology, The First Hospital Affiliated to Army Medical University, Chongqing, China
146 Department of Respiratory, The First Hospital Affiliated to Army Medical University, Chongqing, China
147 rdf:type schema:Organization
148 grid-institutes:grid.412461.4 schema:alternateName Department of Respiratory, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
149 schema:name Department of Respiratory, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
150 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...